Immunomedics wows ESMO with breast cancer data reveal

Immunomedics has revealed the trial data that convinced Gilead to stage a

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.

ESMO 2019 – new data could unlock bigger market for PARP inh...

AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l

ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal...

Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...

Merck KGaA's bold new approach to cancer immunotherapy

Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.